Share on LinkedInShare on LinkedIn

ARTICLE · 16 JULY 2013

A Given Claim Term Can Have Different Meanings In Different Contexts In The Patent

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

In a recent case, the Federal Circuit reversed and remanded the district court's entry of a stipulated judgment of noninfringement, concluding that the district court's Markman opinion misinterpreted claim terms of U.S. Patent No. 5,750,703.

United StatesIntellectual Property

In Aventis Pharmaceuticals, Inc. v. Amino Chemicals Ltd., Nos. 11-1335, -1336 (Fed. Cir. May 20, 2013), the Federal Circuit reversed and remanded the district court's entry of a stipulated judgment of noninfringement, concluding that the district court's Markman opinion misinterpreted claim terms of U.S. Patent No. 5,750,703 ("the '703 patent").

The '703 patent is owned by Albany Molecular Research, Inc. ("AMRI") and directed to processes for making piperidine derivatives used in antihistamine products.  Sanofi-Aventis U.S., the exclusive licensee of the '703 patent, uses the patented process to produce fexofenadine for its Allegra® and Allegra-D® 24 Hour products.  Amino Chemicals Ltd., Dipharma Francis, Sr.L., and Dipharma Spa (collectively "Appellees") are generic drug manufacturers for Mylan Pharmaceutical Inc. ("Mylan") and Teva Pharmaceuticals USA, Inc. ("Teva").  Several generic drug companies, including Mylan and Teva, filed ANDAs with the FDA seeking

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from